^
Association details:
| Biomarker: | EGFR C796S |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | Tagrisso (osimertinib) (EGFR inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
Acquired resistance to osimertinib in patients with non-small-cell lung cancer: mechanisms and clinical outcomes
Published date:
05/10/2020
Excerpt:
We retrospectively analyzed patients with advanced NSCLC who received osimertinib....In patients who developed resistance to osimertinib, possible genomic resistance mutations were identified in 27 of 49 patients in the molecular analysis set. Fourteen patients (14/49, 28.6%) acquired secondary EGFR C797S mutation….A summary of resistance mechanisms to osimertinib are shown in Fig. 2.
DOI:
10.1007/s00432-020-03239-1
